Showing results (51-60 of 649) with videos related to

Sort By:
Pageof 65
Plos One|November 9, 2013
CanDrA: cancer-specific driver missense mutation annotation with optimized featuresYong Mao, Han Chen, Han Liang, et al.
RNA Biology|December 23, 2008
RNA-binding specificity of Y-box protein 1Jinjiang Dong, Argun Akcakanat, David N Stivers, et al.
Endocrine-Related Cancer|March 4, 2008
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumorsAmy Moreno, Argun Akcakanat, Mark F Munsell, et al.
Scientific Reports|July 29, 2022
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenograftsLicai Huang, Jing Wang, Bingliang Fang, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 8, 2025
Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic AdvancesLorenzo Guidi, Julian Etessami, Carmine Valenza, et al.
Cancer Science|March 31, 2011
Nanomedicine in cancer therapy: innovative trends and prospectsElvin Blanco, Angela Hsiao, Aman P Mann, et al.
Oncogene|June 10, 2021
Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutationsMaryam Shariati, Kurt W Evans, Xiaofeng Zheng, et al.
The Lancet. Oncology|February 23, 2010
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient careDebashish Bose, Funda Meric-Bernstam, Wayne Hofstetter, et al.
Molecular Oncology|November 11, 2011
Molecular-targeted nanotherapies in cancer: enabling treatment specificityElvin Blanco, Angela Hsiao, Guillermo U Ruiz-Esparza, et al.
Nature Reviews. Clinical Oncology|October 16, 2023
Molecular tumour boards - current and future considerations for precision oncologyApostolia M Tsimberidou, Michael Kahle, Henry Hiep Vo, et al.
Pageof 65